Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

2.

Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer.

Tsai MS, Shamon-Taylor LA, Mehmi I, Tang CK, Lupu R.

Oncogene. 2003 Feb 6;22(5):761-8.

PMID:
12569369
3.

Proximal events in signaling by plasma membrane estrogen receptors.

Razandi M, Pedram A, Park ST, Levin ER.

J Biol Chem. 2003 Jan 24;278(4):2701-12. Epub 2002 Nov 5.

4.

Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer.

Widschwendter A, Tonko-Geymayer S, Welte T, Daxenbichler G, Marth C, Doppler W.

Clin Cancer Res. 2002 Oct;8(10):3065-74.

6.

Stat proteins and oncogenesis.

Bromberg J.

J Clin Invest. 2002 May;109(9):1139-42. Review. No abstract available.

7.

New functions for the matrix metalloproteinases in cancer progression.

Egeblad M, Werb Z.

Nat Rev Cancer. 2002 Mar;2(3):161-74. Review.

PMID:
11990853
8.
9.

Gelatinase levels in male and female breast cancer.

Giannelli G, Fransvea E, Marinosci F, Bergamini C, Daniele A, Colucci S, Paradiso A, Quaranta M, Antonaci S.

Biochem Biophys Res Commun. 2002 Mar 22;292(1):161-6.

PMID:
11890687
10.

The effect of Neovastat (AE-941) on an experimental metastatic bone tumor model.

Weber MH, Lee J, Orr FW.

Int J Oncol. 2002 Feb;20(2):299-303.

PMID:
11788892
11.

Matrix metalloproteinases in neoplasm-induced extracellular matrix remodeling in breast carcinomas.

Bodey B, Bodey B Jr, Siegel SE, Kaiser HE.

Anticancer Res. 2001 May-Jun;21(3B):2021-8.

PMID:
11497292
12.

Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells.

Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, Cox CE, Falcone R, Fairclough R, Parsons S, Laudano A, Gazit A, Levitzki A, Kraker A, Jove R.

Oncogene. 2001 May 3;20(20):2499-513.

13.

Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients.

Scorilas A, Karameris A, Arnogiannaki N, Ardavanis A, Bassilopoulos P, Trangas T, Talieri M.

Br J Cancer. 2001 Jun 1;84(11):1488-96.

14.

AdTIMP-2 inhibits tumor growth, angiogenesis, and metastasis, and prolongs survival in mice.

Li H, Lindenmeyer F, Grenet C, Opolon P, Menashi S, Soria C, Yeh P, Perricaudet M, Lu H.

Hum Gene Ther. 2001 Mar 20;12(5):515-26.

PMID:
11268284
15.

Matrix metalloproteinases in tumor invasion and metastasis.

Stamenkovic I.

Semin Cancer Biol. 2000 Dec;10(6):415-33. Review.

PMID:
11170864
16.

Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells.

Elenbaas B, Spirio L, Koerner F, Fleming MD, Zimonjic DB, Donaher JL, Popescu NC, Hahn WC, Weinberg RA.

Genes Dev. 2001 Jan 1;15(1):50-65.

17.

Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors.

Hanemaaijer R, Verheijen JH, Maguire TM, Visser H, Toet K, McDermott E, O'Higgins N, Duffy MJ.

Int J Cancer. 2000 Apr 15;86(2):204-7.

18.

bcl-2 over-expression enhances NF-kappaB activity and induces mmp-9 transcription in human MCF7(ADR) breast-cancer cells.

Ricca A, Biroccio A, Del Bufalo D, Mackay AR, Santoni A, Cippitelli M.

Int J Cancer. 2000 Apr 15;86(2):188-96.

20.

cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype.

Smith LM, Wise SC, Hendricks DT, Sabichi AL, Bos T, Reddy P, Brown PH, Birrer MJ.

Oncogene. 1999 Oct 28;18(44):6063-70.

Supplemental Content

Support Center